CYP11B2 and adrenal gland neoplasm: However, De Sousa et al. [14] found that sequenced areas showing KCNJ5 mutations could exhibit heterogeneous expressions of CYP11B2, i.e., KCNJ5 mutation could be identified in CYP11B2 positive or negative adrenal tumors, which may suggest repression of CYP11B2 activity in certain functional tumors by undisclosed mechanisms.